Poor Diet in Adolescence Tied to Cardiometabolic Risk Factors
By Lori Solomon HealthDay Reporter
THURSDAY, Dec. 21, 2023 -- U.S. teens with poor diet quality have cardiometabolic risk factors, according to a research brief published in the December issue of the Journal of Nutrition Education and Behavior.
Kathy Hu, from the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge, and colleagues examined the prospective association among diet with adolescent cardiometabolic risk and anthropometrics over two years. The analysis included 192 adolescents (aged 10 to 16 years) participating in the Translational Investigation of Growth and Everyday Routine in Kids cohort.
The researchers found that baseline Healthy Eating Index-2015 scores were inversely associated with follow-up total cardiometabolic risk z-score, homeostatic model assessment for insulin resistance, waist circumference z-score, body mass index percentile, fat mass, lean mass, and visceral adipose tissue mass.
"Promotion of nutrition knowledge is necessary, but knowledge is not consistently linked with food consumption behavior," senior author Amanda E. Staiano, Ph.D., also from Louisiana State University, said in a statement. "Identifying barriers to consuming a healthful diet and investigating effective strategies to overcome these barriers may curtail future health risks."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-22 02:15
Read more
- Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
- COVID Vaccine Mistrust Levels Aren't Budging, Study Finds
- American College of Gastroenterology, Oct. 25-30
- Get With The Guidelines-Stroke Participation Has Improved Stroke Care
- July 2019 to June 2023 Saw Increase in OD Deaths With Ketamine Detected
- Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions